Bisphenol A May Help Inflammatory Breast Cancer Cells Survive
The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, suggests Duke University research that reveals a potential mechanism for how the disease grows.
Inflammatory breast cancer (IBC) is the most lethal and fastest-growing form of breast cancer and quickly develops resistance to treatments. The new study shows that bisphenol A increases the cell signaling pathway known as mitogen-activated protein kinases, or MAPK, in inflammatory breast cancer cells.
Previous studies have theorized that bisphenol A and other endocrine-disrupting chemicals — which mimic hormones like estrogen in the body — may promote the development of breast tissue tumors. However, this study explored a potential mechanism for how the proliferation happens in an estrogen-independent manner and which specific chemicals might be involved.
Bisphenol A Signalling
Gayathri Devi, associate professor of surgery at Duke University, says:
“The study is the first to show that BPA increased signaling through receptors that communicate with the MAPK pathway and that the presence of BPA may lead to resistance to cancer drugs targeting this pathway,” “In our cell models, more signaling led to increased growth of the cancer cells.”
Researchers began the investigation by treating inflammatory breast cancer cells with six endocrine-disrupting chemicals commonly found in the everyday environment, including in food, medications, and agricultural products. Bisphenol A, along with the chemicals trichloroethane (HPTE) and methoxychlor, caused an increase in signaling to epidermal growth factor receptors (EGFR), which lie on the cell surface.
When the cells were treated with low doses of BPA, for example, EGFR activation nearly doubled. In turn, signaling to the MAPK pathway also increased. This increase was accompanied by a rise in indicators of cancer cell growth.
Epidermal Growth Factor Receptor Effects
The researchers also found that exposing the cancer cells to BPA limited the effectiveness of drugs that work to kill cancer cells by inhibiting EGFR signaling. Steven Patierno, PhD, professor of medicine at Duke and study coauthor, said:
“When EGFR-targeted, anti-cancer drugs are unable to decrease the amount of EGFR signaling, it leads to less cell death. This suggests that chemical exposure could help generate a type of breast cancer that might be resistant to the very drugs we use to treat it.”
The research is an addition to a growing body of work that offers greater insight into IBC’s aggressive nature. For example, in another study published recently in the journal Oncotarget, researchers identified specific anti-cell death proteins that are overexpressed in IBC patient tumors.
“Ultimately, we hope that this kind of work will help us develop more effective treatments for IBC, so that survival rates improve,” Devi says.
The study was funded by The Duke Cancer Institute Cancer and Environment Development Funds, a Bolognesi award to Devi from the Duke Department of Surgery, the Duke IBC Consortium funds, the American Cancer Society, and the National Cancer Institute.